Cargando…
Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer
BACKGROUND: To compare the PSA value at the last follow-up of patients who underwent prostate low-dose rate brachytherapy (LDR-BT) with that of patients who underwent intensity-modulated radiation therapy (IMRT). METHODS: A total of 610 prostate cancer patients (cT1c-3bN0M0) were enrolled, and 445 o...
Autores principales: | Tanaka, Nobumichi, Asakawa, Isao, Nakai, Yasushi, Miyake, Makito, Anai, Satoshi, Fujii, Tomomi, Hasegawa, Masatoshi, Konishi, Noboru, Fujimoto, Kiyohide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574121/ https://www.ncbi.nlm.nih.gov/pubmed/28841855 http://dx.doi.org/10.1186/s12885-017-3565-1 |
Ejemplares similares
-
Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancer
por: Nakai, Yasushi, et al.
Publicado: (2019) -
Quality of life in patients who underwent (125)I brachytherapy, (125)I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer
por: Nakai, Yasushi, et al.
Publicado: (2019) -
Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer
por: Tanaka, Nobumichi, et al.
Publicado: (2012) -
Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer
por: Onishi, Kenta, et al.
Publicado: (2018) -
Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil -
por: Tanaka, Nobumichi, et al.
Publicado: (2014)